Hyperfine (HYPR) Q3 2026 earnings review
Hyperfine's scanner sales jump, and revenue tops cash burn
Hyperfine, the maker of the Swoop portable brain MRI scanner, brought in more revenue than the cash it burned for the first time. Preliminary third-quarter sales jumped 53% from the prior quarter to $6.0 million, while net cash outflow dropped to $5.6 million without any new stock sales. Chief executive Maria Sainz kept the full-year outlook unchanged, which by our math leaves $6.2 million to $8.2 million of sales for the fourth quarter.
| Preliminary Q3 revenue | $6.0M +53% from last quarter; +76% from a year ago by our math |
|---|---|
| Preliminary Q3 net cash burn | $5.6M down 29% from $7.9M last quarter |
| Cash and cash equivalents | $37.9M $0 raised from stock or debt in Q3 |
| Full-year revenue outlook | Unchanged $20–22M (middle of the range: 55% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because the third-quarter sales jump makes the full-year target realistic after two flat quarters had put it in doubt. Hospital repeat orders and European launches lifted revenue while cash burn fell inside the pace implied by the annual plan. One caution: today's update is preliminary, so unit counts, gross margin, and customer concentration wait until the November 9 report.
The question now is whether the third-quarter surge marks a lasting step-up in hospital and clinic demand or a lumpy cluster of orders. If hospital groups keep adding scanners across sister sites, fourth-quarter sales should clear the $7.2 million middle of the implied range; if a few large buyers drove the quarter, growth could stall against last year's upgrade-boosted comparison. The unit count and order backlog on November 9 will tell.
🐂 Bull Case
Revenue Topped Cash Burn for the First Time
Hyperfine makes the Swoop system, a portable brain MRI scanner that rolls to a patient's bedside. Since its founding, the medical device maker has spent more cash each quarter than it brought in from sales. Chief executive Maria Sainz said "strong operating discipline is reflected in lower cash burn" as preliminary third-quarter revenue topped cash outflow for the first time.
- Preliminary third-quarter revenue: about $6.0 million, up 53% from last quarter and up 76% from a year ago by our math
- Preliminary net cash burn: about $5.6 million, down 29% from $7.9 million in the second quarter
- Full-year gross margin plan: held at 50% to 55% in the investor presentation, up from 49.8% in 2025
This crossover matters because the US company had burned roughly two dollars of cash for every dollar of sales during the first half of 2026. Higher scanner volume and lower research spending narrowed that gap without needing higher headcount.
What to watch: audited third-quarter gross margin on November 9. Holding above 50% would confirm that full-price scanner sales, rather than discounting, drove the revenue jump.
Health Systems and Clinics Drove the Jump
After two flat quarters at $3.9 million, Hyperfine needed its new sales channels to turn trials into multi-unit orders. Sainz said "execution of our commercial strategy is driving meaningful growth" across hospital networks, private neurology clinics, and international distributors.
The company reported "new and follow-on orders from health systems" alongside the "rollout of our Model 2 Swoop system in international markets" after winning European clearance Earlier this year. In private clinics, doctors have now run more than 3,000 brain scans in the first year since launch. Because hospital groups test one unit before buying for sister sites, repeat orders shorten the sales cycle.
What to watch: the exact count of commercial Swoop systems sold when full results arrive on November 9. A jump well above the 12 units sold in the second quarter would prove broad unit demand.
Contrast Study Finished Enrollment Ahead of Filing
Private neurology clinics often require MRI scans using gadolinium contrast, an injected dye that highlights tumors and inflammation. Hyperfine has been running its Contrast PMR clinical trial to add this capability to the Swoop scanner's regulatory label.
In the October presentation, the scanner maker disclosed that enrollment in the Contrast PMR study is now complete, up from roughly three-quarters full last quarter. It also won US regulatory clearance in August for its twelfth-generation Optive AI software, which improves image clarity and rolled out in September. Completing the trial on time keeps the year-end regulatory filing on track.
What to watch: confirmation of the formal US regulatory submission by December 31, 2026. Filing on schedule sets up potential clearance next year to unlock dedicated outpatient insurance codes.
🐻 Bear Case
Fourth-Quarter Sales Still Need Another Record Jump
Sainz called the third quarter a major step up and kept the full-year revenue outlook at $20 million to $22 million. While the $6.0 million quarter makes the annual target much more plausible than it looked in August, the math for the final three months remains steep.
- Nine-month preliminary revenue: $13.8 million, up 66% from $8.3 million a year ago
- Fourth-quarter revenue implied by the full-year plan: $6.2 million to $8.2 million ($7.2 million at the middle of the range) by our math
- Fourth-quarter 2025 comparison base: $5.3 million, which included one-off paid hardware upgrades across existing customers
Hitting the middle of the full-year plan requires fourth-quarter sales to rise another 20% from the third quarter's record level, by our math. That also means growing 36% over a year-ago quarter boosted by one-time upgrade fees, and the company cut or missed its initial annual targets in both 2024 and 2025.
What to watch: management's commentary on fourth-quarter order backlog on the November 9 call. Anything short of contracted orders covering at least $6.2 million would leave the full-year floor at risk.
Key Unit and Margin Numbers Wait Until November
Because today's announcement is a preliminary update subject to "the completion of the Company’s quarter-end closing procedures", several standing questions received no numbers. The full accounting arrives on November 9.
- Commercial scanner units sold and average selling price: omitted from the preliminary release; the quarterly filing will show whether volume or price drove the $6.0 million top line.
- Split between hospital, neurology office, and international sales: not quantified; the earnings call will test whether private clinics are scaling beyond early adopters.
- Customer concentration and single-manufacturer reliance: three buyers made up 41% of second-quarter sales, and the quarterly filing's footnotes will show if third-quarter growth relied on a few large deals.
What to watch: the unit count and customer concentration footnote in the third-quarter filing on November 9. Broad unit growth across many buyers would ease concerns about lumpy hospital orders.
No Share Sales in Q3, But Funding Limits Remain
Hyperfine has funded its operations over the past two years by issuing stock and taking on high-interest debt, lifting its Class A share count from 58 million at the end of 2024 to 91 million by June 2026. In the second quarter alone, it raised $10.6 million by selling shares on the open market.
During the third quarter, the portable MRI maker raised $0.0 million from financing and ended September with $37.9 million in cash. At the improved $5.6 million quarterly burn rate, that cash lasts nearly seven quarters by our math, supporting the company's plan for cash to last into 2028. Still, borrowing the remaining $25 million under its $40 million loan facility requires hitting undisclosed sales milestones.
What to watch: net cash burn in the fourth quarter, which the full-year outlook implies at about $4.8 million by our math. Staying near or below $5 million keeps the company from needing to sell more stock.
💲 Other KPIs
Cash dipped 12.9% from $43.5 million in June because Hyperfine sold no new stock or debt this quarter, but the balance stays 75.5% higher than the $21.6 million held a year ago. With quarterly cash burn down to $5.6 million, the current reserve covers nearly seven quarters of operations by our math.
The total number of commercial and research Swoop scanners placed worldwide passed 225 in September, up at least 12.5% from 200 systems at the end of 2025 by our math. A larger installed base builds recurring service and software fees, which made up about 19% of sales in the first half.
🔮 Guidance
Unchanged. Management kept its full-year target calling for 55% growth at the $21 million middle of the range. By our math, after $13.8 million in the first nine months, the plan leaves $6.2 million to $8.2 million for the fourth quarter ($7.2 million at the middle, or 36% growth from a year ago against a tough upgrade comparison).
Unchanged. The plan still calls for full-year cash outflow to drop 10% at the $27 million middle of the range compared with $29.9 million in 2025. By our math, with $22.2 million burned through September, the outlook implies fourth-quarter cash burn of $3.8 million to $5.8 million ($4.8 million at the middle, down 16% from a year ago).
Unchanged. The October investor presentation reaffirmed the full-year gross margin target of 50% to 55%, up from 49.8% in 2025. Higher factory volume and higher prices on the Model 2 scanner support the expansion, though the company has not yet reported the third-quarter margin figure.
❓ Key Questions
How many scanners did Hyperfine sell in the third quarter?
Revenue jumped 53% from the second quarter to $6.0 million, but the preliminary release gave no unit count. Investors need to know on November 9 how many systems shipped above last quarter's 12 units and how much came from higher prices.
What share of third-quarter sales came from neurology offices?
Management highlighted 3,000 office scans in the vertical's first year, yet stopped giving office unit counts earlier in 2026. Breaking out placements across hospitals, private clinics, and foreign distributors will show which channel drove the rebound.
How much of the fourth-quarter target is already in backlog?
By our math, meeting the $20 million to $22 million full-year plan requires $6.2 million to $8.2 million in fourth-quarter sales. Because hospital purchasing cycles are lumpy, investors need to know what share of that target is already contracted.
What sales milestones unlock the remaining $25 million loan?
Hyperfine drew $15 million of its $40 million debt facility in March, but the remaining $25 million requires hitting commercial targets through December 2027. Disclosing whether third-quarter sales met those conditions clarifies long-term liquidity.